The Pezcoller Symposia

Session I, The Krebs Cycle and Cancer Cells
Chair/Moderator: William Kaelin
9:30 William Kaelin
9:55 Discussion
10:15 Coffee break
10:30 Katherine Wells
10:55 Discussion
11:15 Eyal Gottlieb
11:40 Discussion
12:00 Ann Brunet
12:25 Session II, Metabolic Pathways in Cancer Cells
Chair/Moderator: Karen Vousden
14:30 Karen Vousden
14:55 Discussion
15:15 Reuben Shaw
15:40 Discussion
16:00 David Sabatini
16:25 Discussion
16:45 Almut Schulze
17:10 Discussion
17:30 Graham Hardie
17:55 Discussion
18:15 Adjourn
16:45 – Metabolic reprogramming in cancer supports cell growth and survival
17:30 – AMP-activated protein kinase: friend or foe in cancer?
18:15 – Keynote Address: Choking cancer via inhibition of a tumor-essential metabolic enzyme dispensable to normal tissues

Session III, Modeling Cancer Metabolism
Chair/Moderator: Massimo Loda
8:30 Massimo Loda
8:55 Discussion
9:15 Owen Sansom
9:40 Discussion
10:00 Coffee break
10:20 Gerry Melino
10:45 Discussion
11:05 Eytan Ruppin
11:30 Discussion
11:50 Poster Session & Lunch
11:50 – The VHL Tumor Suppressor: Insights into oxygen sensing and cancer metabolism
10:00 – Metabolic reprogramming: links to the epigenome
10:20 – Characterizing and targeting cancer metabolic liabilities
11:05 – Epigenetic and metabolic regulation of aging
11:50 – Macrophage polarization and orchestration of metabolism

Session IV, Imaging and New Technologies
Chair/Moderator: Elizabeth Maher
9:45 Discussion
9:25 Discussion
9:00 Katharine Yen
9:25 Discussion
9:45 Richard Wooster
10:10 Discussion
10:30 Ray Pagliarini
10:50 Discussion
11:20 Peter Jackson
11:45 Discussion
12:05 David Livingston
12:30 Lunch & Adjourn
9:00 – IDH mutations and tumorigenicity
9:25 – The metabolic and biological consequences of inhibiting fatty acid synthase in cancer
9:45 – Characterizing IDH Mutations in Cancer
10:10 – Targeting glycolysis and adaptation to glycolytic inhibition
10:30 – Concluding Remarks

Invited Participants
- Kevin Brindle
  Cambridge Research Inst, Cambridge, UK
- Anne Brunet
  Stanford Univ School of Medicine, Stanford, CA
- Eyal Gottlieb
  The Beatson Inst for Cancer Res, Glasgow, Scotland
- Graham Hardie
  Univ of Dundee, Dundee, Scotland, UK
- Peter Jackson
  Genentech, San Francisco, CA
- William Kaelin
  Dana Farber Cancer Inst, Boston, MA
- David Livingston
  Dana Farber Cancer Inst, Boston, MA
- Massimo Loda
  Harvard Medical School, Dana Farber Cancer Inst, Boston, MA
- Elizabeth Maher
  UT Southwestern Medical Ctr, Dallas, TX
- Alberto Mantovani
  Istituto Clinico Humanitas, Milan, Italy
- Steven McKnight
  The Beatson Inst for Cancer Res, Glasgow, Scotland
- Enrico Mihich
  Dana Farber Cancer Inst, Boston, MA
The Pezcoller Foundation

The Pezcoller Foundation is a non-profit organisation created in 1980 by Prof. Alessio Pezcoller (1896 - 1993), Chief Surgeon at Santa Chiara Hospital of Trento, Italy. The goal of the Foundation is to promote biomedical research.

Activities:
- PEZCOLLER FOUNDATION-AACR INTERNATIONAL AWARD FOR CANCER RESEARCH – 75,000 Euro: this prize is presented, every year, to a scientist who has made a major scientific discovery in the field of cancer.
- PEZCOLLER FOUNDATION-ECCO RECOGNITION FOR CONTRIBUTION TO ONCOLOGY – 30,000 Euro: this prize is presented, every two years, to a single individual (scientist, clinician, nurse, etc.) for his/her professional life dedication to the improvement of cancer treatment, care and research.
- THE PEZCOLLER SYMPOSIUM: a series of annual symposia promoting interactions among scientists working at the cutting edge of basic oncological sciences.
- PEZCOLLER SEMINARS: a series of educational meetings for medical doctors.
- PEZCOLLER FOUNDATION FELLOWSHIPS: for professional updating in oncology.
- PEZCOLLER FOUNDATION GRANTS: for oncological research programs.
- THE PEZCOLLER FOUNDATION JOURNAL: this periodical is published to provide a direct link, at six month interval, between the Pezcoller Foundation and the international medical and scientific community.
- PEZCOLLER-EACR AWARD: celebrating academic excellence and achievements of young European researchers in the field of cancer. This prestigious award and lecture is presented at the Biennial EACR Congress. The award includes 10,000 Euro plus expenses covering travel, accommodation and congress fees.

This Symposium is supported by:
- Fondazione Cassa di Risparmio di Trento e Rovereto
- Provincia Autonoma di Trento
- Comune di Trento
- Comune di Rovereto
- Novartis Inst for Biomedical Res, Cambridge, MA
- Tel Aviv University, Tel Aviv, Israel
- Massachusetts Inst of Technology, Cambridge, MA
- Harvard University, Cambridge, MA
- The Beatson Inst for Cancer Res, Glasgow, Scotland
- London Res Inst, London, UK
- Salk Inst for Biological Studies, La Jolla, CA
- The Beatson Inst for Cancer Res, Glasgow, Scotland
- Unv of Pennsylvania, Philadelphia, PA
- California Inst of Technology, Pasadena, CA
- GlaxoSmithKline, Collegeville, PA
- Agios Pharmaceuticals, Cambridge, MA

The Pezcoller Foundation Symposium

25th Pezcoller Symposium
METABOLISM AND TUMORIGENESIS
Trento, Italy, June 20-22, 2013

Invited Participants
- Ray Pagliarini
  Novartis Inst for Biomedical Res, Cambridge, MA
- Eytan Ruppin
  Tel Aviv University, Tel Aviv, Israel
- David Sabatini
  Massachusetts Inst of Technology, Cambridge, MA
- Alan Saghatelyan
  Harvard University, Cambridge, MA
- Oween Sansom
  The Beatson Inst for Cancer Res, Glasgow, Scotland
- Almut Schulze
  London Res Inst, London, UK
- Reuben Shaw
  Salk Inst for Biological Studies, La Jolla, CA
- Karen Vousden
  The Beatson Inst for Cancer Res, Glasgow, Scotland
- Katherine Wellen
  Univ of Pennsylvania, Philadelphia, PA
- Linda Wilson
  California Inst of Technology, Pasadena, CA
- Richard Wooster
  GlaxoSmithKline, Collegeville, PA
- Katharine Yen
  Agios Pharmaceuticals, Cambridge, MA

Tumor cells often reveal complex sets of metabolic abnormalities. Certain metabolic abnormalities in tumors are grounded in the operations of mutant or dysfunctional genes, underscoring the value of these perturbations in the tumorigenesis process. This Symposium will explore key aspects of cancer cell metabolism with an emphasis on understanding the mechanisms that give rise to it, on defining how it serves the survival needs of tumors, on identifying abnormal tumor metabolic phenotypes, and on assessing the potential clinical effects of interfering with these abnormalities.